Backgrounds/Aims: Approximately 60-80% of patients with intrahepatic cholangiocarcinoma (iCCA) are not suitable for surgical resection due to advanced disease at presentation. This review assesses the role of surgical resection followed by down staging treatment in the management of patients with locally advanced iCCA. Methods: A systematic review and pooled analysis were performed of the relevant published studies published between January 2000-December 2018. The primary outcome measure was overall survival. Secondary outcome measures were rates of clinical benefit, margin-negative (R0) resections, overall and surgery-specific complications, and post-operative mortality. Results: Eighteen cohort studies with 1880 patients were included in the review. The median overall survival in all patients was 14 months (range, 7-18 months). Patients undergoing resection following down staging had significantly longer survival than those who did not (median: 29 vs. 12 months, p＜0.001). The Clinical Benefit Rate with this strategy (complete response+partial response+stable disease) was 64% (244/383), ranging from 33-90%. Thirty-eight percent of the patients underwent resections with a 60% R0 resection rate and 6% postoperative mortality. Conclusions: Although the evidence to support the benefits of NAT for iCCA is limited, the review supports the use of down staging treatment and also surgical resection in the cohort with response to NAT in order to improve long-term survival in patients with locally advanced iCCA. (Ann Hepatobiliary Pancreat Surg 2020;24:6-16)
INTRODUCTION
The incidence of intrahepatic cholangiocarcinoma (iCCA) is about 0.7 cases per 100,000 adults in the USA. 1 Despite advances in multimodality treatment, long-term survival is only seen in 10-20% of patients due to the advanced stage at presentation. 2 Surgical resection remains the only potentially curative therapy for patients with iCCA; however, only 30-60% of patients are candidates for surgical resection due to locally advanced (large tumors with either hepatic inflow or outflow involvement) or metastatic disease, underlying chronic liver disease, or frailty. 3 In patients undergoing surgical resection, the 5-year survival is 20-40%, and median survival is 25 months. 3 In patients with unresectable disease, median survival is 12-15 months with a 5-year survival of 5-10%, 4, 5 with chemotherapy based on a combination of gemcitabine and platinum salts. 6 There is no established standard treatment for patients with locally advanced biliary cancers. The role of chemotherapy or radiotherapy is considered mainly a palliative in unresectable iCCA. Neoadjuvant therapy (NAT) with a view to downstage has gained popularity in the last decade in the management of hepatobiliary and pancreatic cancers, particularly the latter in patients with borderline resectable and locally advanced (LA) cancers.
Pooled analysis by Suker et al. 7 in a systematic review demonstrated NAT with FOLFIRINOX for locally advanced pancreatic cancers had a median overall survival (OS) ranging between 10 and 33 months and resection rates of up to 43%. In resectable oesophageal cancers, NAT has been demonstrated standard treatment through high-quality randomized controlled trials. 8 A recent network metaanalysis further demonstrated neoadjuvant CRT (chemoradiotherapy) followed by surgery to be the most effective strategy in improving long-term survival of resectable oesophageal cancers. 9 To date, there is limited consensus for advocating NAT for patients with iCCA to further improve survival and surgical outcomes. For the purpose of the study, this was considered downstaging treatment given to patients with non-metastatic iCCA as NAT, although the intention might have been palliation given the clinical practice during the study period. Hence, the aim of this review is to determine the oncological and surgical outcomes of patients receiving NAT for borderline iCCA. 
METHODS

Search strategy
Data extraction
Study outcomes
RESULTS
Study characteristics
The literature search identified 18 cohort studies, including 1880 patients with locally advanced iCCA, of which two were prospective cohort studies. Baseline demographics of the included studies are presented in Table 1 .
Study quality was assessed using NewCastle Ottawa system. Ten studies provided the definitions for locally advanced or inoperable iCCA, and these are detailed in Table 2 .
Chemotherapy and radiotherapy regimes
NAT regimes and tumor responses are presented in Table 3 . Eleven studies reported the use of neoadjuvant chemotherapy, of which four 10, 11, 14, 15 reported the use of transarterial chemoembolization (TACE) with mitomycin C (MMC). One study 14 used gemcitabine and cisplatin in addition to MMC for TACE. Eight studies 5, 12, [17] [18] [19] [20] 22, 26 evaluated combinations of chemotherapy (gemcitabine/capecitabine and platinum-based regimes). Of the remaining studies, one reported use of RT, 13 three reported use of chemoradiotherapy (CRT), 16, 23, 25 and one compared concurrent CRT, chemotherapy and RT, chemotherapy, and no treatment.
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Response rates and the definitions of response Eleven studies reported the criteria used to assess tumour response [RECIST (n=9), 10, 11, 14, 16, 17, 19, 21, 23, 25 mRECIST (n=1), 5 and WHO (n=1)]. 12 Nine studies 5, [10] [11] [12] [13] [14] 16, 17, 25 
Resectability rates
Of the nine studies 5, [10] [11] [12] [13] [14] 16, 17, 25 (383 patients) where response rates were provided, 64% (244/383) showed a clinical benefit for NAT. None of the studies provided the number of patients who were explored for but failed to proceed to resection following NAT. Of the studies 5, 17, [19] [20] [21] [22] 25, 26 where post-NAT resection rates were reported, 135/354 patients (38%) underwent resections. Of these, 60% of the patients had R0 resections (82/135 patients), 40% were reported to have R1 resection, and R2 resection was performed in 1/135 patients.
Overall survival
The OS of the entire cohort was 14 months (range, (Table 4) .
Postoperative outcomes
Overall post-surgical complications were reported in eight studies. 5, 17, [19] [20] [21] [22] 25, 26 The overall rate of postoperative mortality was 6% (8/135 patients) on pooled analysis. The rate of major complications was 15.5% (21/135 patients).
Bile leaks (four patients), post-hepatectomy liver failure (four patients), intraabdominal collections (four patients), ascites (three patients), post-operative bleeding (one patient), pleural effusion (one patient), and acute kidney injury (one patient) were the reported complications (Table   5 ).
DISCUSSION
Over the last decade, the long-term survival of patients diagnosed with iCCA has been relatively poor, with a small proportion of patients undergoing curative surgical resection and a median survival of 20-30 months in the resected group. 3 NAT for iCCA is an appealing option for suitable candidates to select the patient with less aggressive tumor biology, downstage the disease, increase The present review highlights that current evidence for NAT in iCCA is limited to cohort studies, specifically retrospective case series. This review further highlights that NAT followed by resection has a superior survival rate than patients receiving NAT alone or no surgery in the group of patients deemed unresectable because of locally advanced disease.
Le Roy et al. 5 reported no significant difference in the patients who had primarily resectable and downstaged un- Table 2) . We propose that the HPB surgical community should aim to obtain consensus for the definition of borderline resectability and selection of iCCA patients for NAT. In this group of patients, NAT might be able to increase resectability rates, with acceptable morbidity, mortality, and prolonged survival. 
